via MS Society UK
A new study shows that intense immunosuppression followed by a hematopoietic stem cell transplant may prevent disability associated with multiple sclerosis (MS) from getting worse in 71% of people with relapsing-remitting MS for up to 10 years after the treatment.
The research is published in the January 20, 2021, online issue of Neurology®, the medical journal of the American Academy of Neurology. The study also found that in some people their disability improved over 10 years after treatment. Additionally, more than half of the people with the secondary progressive form of MS experienced no worsening of their symptoms 10 years after a transplant.
While most people with MS are first diagnosed with relapsing-remitting MS, marked by symptom flare-ups followed by periods of remission, many people with relapsing-remitting MS eventually transition to secondary progressive MS, which does not have wide swings in symptoms but instead a slow, steady worsening of the disease.
The study involved autologous hematopoietic stem cell transplants, which use healthy blood stem cells from the participant’s own body to replace diseased cells.
“So far, conventional treatments have prevented people with MS from experiencing more attacks and worsening symptoms, but not in the long term,” said study author Matilde Inglese, M.D., Ph.D., of the University of Genoa in Italy and a member of the American Academy of Neurology. “Previous research shows more than half of the people with MS who take medication for their disease still get worse over a 10-year period. Our results are exciting because they show hematopoietic stem cell transplants may prevent someone’s MS disabilities from getting worse over the longer term.”
The study looked at 210 people with MS who received stem cell transplants from 1997 to 2019. Their average age was 35. Of those people, 122 had relapsing-remitting MS and 86 had secondary progressive MS and two had primary progressive MS.
Researchers assessed participants at six months, five years and 10 years after their transplants.
Five years into the study, researchers found that 80% of the people experienced no worsening of their MS disability. At the 10-year mark, 66% still had not experienced a worsening of disability.
When looking at just the people with the most common form of MS, researchers found 86% of them experienced no worsening of their disability five years after their transplant. Ten years later, 71% still experienced no worsening of their disability.
Also, people with progressive MS benefited from stem cell transplants. Researchers found that 71% of the people with this type of MS experienced no worsening of their disability five years after their transplants. Ten years later, 57% experienced no worsening of their disability.
“Our study demonstrates that intense immunosuppression followed by hematopoietic stem cell transplants should be considered as a treatment for people with MS, especially those who don’t respond to conventional therapy,” Inglese said.
Limitations of the study include that it was retrospective, did not include a control group and the clinicians who helped measure participants’ disability were aware that they had received stem cell transplants, so that could have led to bias. Inglese said these limitations will be addressed in future research.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Stem cell transplant
- Georgia Cancer Center celebrates 1,000th stem cell transplanton August 3, 2021 at 10:16 am
A Savannah-area woman became the 1,000th patient to receive a bone marrow transplant at Georgia Cancer Center at Augusta University.
- Study confirms safety of stem cell therapy for chronic knee painon August 3, 2021 at 7:12 am
A study released in Stem Cells Translational Medicine has confirmed the safety of a novel type of cellular therapy for knee pain caused by osteoarthritis. Conducted by a multi-institutional team of ...
- Safety of Stem Cell Therapy for Chronic Knee Pain Confirmed in New Studyon August 3, 2021 at 6:00 am
A study released in STEM CELLS Translational Medicine has confirmed the safety of a novel type of cellular therapy for knee pain caused by osteoarthritis. Conducted by a multi-institutional team of ...
- Global Hematopoietic Stem Cell Transplantation Market to 2027 - Size, Share, Outlook, and Opportunity Analysis - ResearchAndMarkets.comon August 3, 2021 at 3:59 am
Market - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027" report has been added to ResearchAndMarkets.com's offering.
- Insights on the Hematopoietic Stem Cell Transplantation Global Market to 2027 - Key Drivers, Restraints and Opportunitieson August 3, 2021 at 2:28 am
The "Hematopoietic Stem Cell Transplantation (HSCT) Market - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027" report has been added to ResearchAndMarkets.com's offering. Hematopoietic stem ...
Go deeper with Google Headlines on:
Stem cell transplant
Go deeper with Bing News on:
- Multiple Sclerosis Drugs Market to Exhibit a 6.7% CAGR, Active Government Support Pushes Growth: Fortune Business Insightson August 4, 2021 at 1:09 am
A non-profit organization called Institute for Clinical and Economic Review (ICER) found that the U.S. spends around US$ 28,000 Mn every year for the treatment of multiple sclerosis. This will fuel ...
- Multiple Sclerosis Key Opportunities and Forecasts to 2023on August 3, 2021 at 3:56 am
Multiple sclerosis (MS) is an inflammatory disease in which the myelin sheaths around the axons of the brain and spinal cord are damaged, leading to demyelination and a wide range of signs and ...
- Multiple Sclerosis Association seeks participants for health surveyon August 2, 2021 at 4:49 am
Cyprus Multiple Sclerosis Association has called on locals to participate in an international survey to evaluate health care procedures. In a social media post inviting people to participate in the ...
- Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosison August 2, 2021 at 4:30 am
Results show that every six-week natalizumab IV administration provides a high level of efficacy in controlling MS disease activity in patients who switched from the approved every four-week dosing ...
- Mapping of multiple sclerosis cases beginson August 1, 2021 at 6:29 pm
People living with MS are at the risk of being overlooked as there is no comprehensive data on them in the country ...